NewEdge Advisors’s VanEck Biotech ETF BBH Stock Holding History

NewEdge Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.87K	Sell	34 -3	-8%	-$564	﹤0.01%	3634
2026 Q1	$6.92K	Sell	37 -2	-5%	-$385	﹤0.01%	3489
2025 Q4	$7.34K	Hold	39	–	–	﹤0.01%	3564
2025 Q3	$6.39K	Hold	39	–	–	﹤0.01%	3459
2025 Q2	$5.92K	Hold	39	–	–	﹤0.01%	3367
2025 Q1	$6.07K	Hold	39	–	–	﹤0.01%	3247
2024 Q4	$6.06K	Buy	39 +1	+3%	+$168	﹤0.01%	3179
2024 Q3	$6.8K	Hold	38	–	–	﹤0.01%	3061
2024 Q2	$6.45K	Hold	38	–	–	﹤0.01%	3006
2024 Q1	$6.37K	Hold	38	–	–	﹤0.01%	3051
2023 Q4	$6.33K	Sell	38 -20	-34%	-$3.08K	﹤0.01%	3038
2023 Q3	$9.07K	Hold	58	–	–	﹤0.01%	2600
2023 Q2	$9.09K	Hold	58	–	–	﹤0.01%	2628
2023 Q1	$9.44K	Buy	58 +13	+29%	+$2.1K	﹤0.01%	2585
2022 Q4	$7	Buy	+45	New	+$7.13K	﹤0.01%	3749

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors's BBH Position: Q2 2026 in Review

NewEdge Advisors reduced its VanEck Biotech ETF (BBH) stake by 8.1% in Q2 2026, selling an estimated $564 and leaving 34 shares worth $6.87K. The position accounts for ﹤0.01% of the portfolio, ranked #3634.

NewEdge Advisors first reported a position in BBH in Q4 2022 and has held it in 15 quarters since. The position peaked at $9.44K in Q1 2023. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

NewEdge Advisors held 34 shares of VanEck Biotech ETF worth $6.87K as of Q2 2026.
NewEdge Advisors sold 3 VanEck Biotech ETF shares in Q2 2026, an estimated $564.
VanEck Biotech ETF made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3634 holding.
NewEdge Advisors first reported a position in VanEck Biotech ETF in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's VanEck Biotech ETF position peaked at $9.44K in Q1 2023.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.